Status of KRAS in iPSCs Impacts upon Self-Renewal and Differentiation Propensity

Stem Cell Reports. 2018 Aug 14;11(2):380-394. doi: 10.1016/j.stemcr.2018.06.008. Epub 2018 Jul 5.

Abstract

Oncogenic KRAS mutations in hematopoietic stem cells cause RAS-associated autoimmune lymphoproliferative syndrome-like disease (RALD). KRAS plays essential roles in stemness maintenance in some types of stem cells. However, its roles in pluripotent stem cells (PSCs) are poorly understood. Here, we investigated the roles of KRAS on stemness in the context of induced PSCs (iPSCs). We used KRAS mutant (G13C/WT) and wild-type isogenic (WT/WT) iPSCs from the same RALD patients, as well as wild-type (WTed/WT) and heterozygous knockout (Δed/WT) iPSCs, both obtained by genome editing from the same G13C/WT clone. Compared with WT iPSCs, G13C/WT iPSCs displayed enforced retention of self-renewal and suppressed capacity for neuronal differentiation, while Δed/WT iPSCs showed normalized cellular characteristics similar to those of isogenic WTed/WT cells. The KRAS-ERK pathway, but not the KRAS-PI3K pathway, was shown to govern these G13C/WT-specific phenotypes, indicating the strong impact of the KRAS-ERK signaling upon self-renewal and differentiation propensity in human iPSCs.

Keywords: KRAS; MAPK pathway; RAS-associated autoimmune lymphoproliferative syndrome-like disease; differentiation; iPSCs; self-renewal; stemness.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Alleles
  • Autoimmune Lymphoproliferative Syndrome
  • Cell Differentiation* / drug effects
  • Cell Differentiation* / genetics
  • Cell Self Renewal* / drug effects
  • Cell Self Renewal* / genetics
  • Cells, Cultured
  • Chromosome Aberrations
  • DNA Mutational Analysis
  • Extracellular Signal-Regulated MAP Kinases / metabolism
  • Gene Editing
  • Gene Expression Profiling
  • Genotype
  • Humans
  • Induced Pluripotent Stem Cells / cytology*
  • Induced Pluripotent Stem Cells / drug effects
  • Induced Pluripotent Stem Cells / metabolism*
  • Karyotype
  • Molecular Imaging
  • Mutation
  • Protein Kinase Inhibitors / pharmacology
  • Proto-Oncogene Proteins c-akt / metabolism
  • Proto-Oncogene Proteins p21(ras) / genetics*
  • Proto-Oncogene Proteins p21(ras) / metabolism
  • Signal Transduction / drug effects

Substances

  • KRAS protein, human
  • Protein Kinase Inhibitors
  • Proto-Oncogene Proteins c-akt
  • Extracellular Signal-Regulated MAP Kinases
  • Proto-Oncogene Proteins p21(ras)